Once integration is completed, the partners plan to accelerate commercial rollout across India, anticipated in 2026.

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced the launch of PrecisionCHD™, an ...

Cardio Diagnostics Holdings Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, is making progress in gaining broad access to Medicare reimbursement for its Epi+Gen CHD™ and ...

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics, Inc, a biotechnology company making cardiovascular disease prevention and early detection more accessible, personalized and precise, announces the launch ...

One of the strongest predictors of long-term mortality among patients undergoing a cardiac stress test is the need for a pharmacologic versus treadmill test, new data show. Moreover, although the risk ...

Cardio Diagnostics Holdings will partner with a longtime distribution leader in India and an Indian network of nearly 300 ...

The final gapfill payment rate for both the Epi+Gen CHD™ and PrecisionCHD™ tests is higher at $854 compared to the preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and $684.76 for ...

Plenty of research touts the importance of cardiorespiratory fitness (CRF)—also known as cardio fitness, cardiovascular endurance, and aerobic fitness—as a health marker, as well as an athletic ...